Standardized tumor rates for chronic bioassays.
If crude experimental proportions of animals with tumors from chronic bioassays for carcinogenicity are used for low-dose extrapolation in a risk analysis, different dose-specific patterns of mortality due to competing risks can bias the results. In order to adjust tumor rates for differential mortality across dose groups, Farmer, Kodell, and Gaylor (1982, Risk Analysis 2, 27-34) recommended using nonparametric estimates of probability distributions of times to onset of tumors, with competing causes of death removed, when performing a risk analysis. This paper extends the approach of Farmer et al. by proposing a method for adjusting tumor rates to reflect lifetime or near-lifetime tumor incidences that would be obtained if all dose groups experienced the control mortality rate from causes other than the tumor of interest. Thus, natural mortality due to competing risks is explicitly included, rather than removed. The proposed standardized tumor rates are calculated as a summation of adjusted age-specific probabilities of dying with a tumor during the course of an animal bioassay for carcinogenicity plus the probability of being alive with a tumor at the terminal sacrifice.
D000818:Animals; D002273:Carcinogens; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005260:Female; D008770:Methylnitrosourea; D009374:Neoplasms, Experimental / Q000473:pathology*; D051381:Rats; D011919:Rats, Inbred Strains; D012306:Risk; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000473:pathology
D002273:Carcinogens; D008770:Methylnitrosourea